Other equities research analysts have also issued research reports about the stock. Cowen reiterated a market perform rating and issued a $36.00 price objective (up previously from $30.00) on shares of Mylan in a research note on Thursday, October 5th. Mizuho reiterated a buy rating and issued a $37.00 price objective on shares of Mylan in a research note on Tuesday, October 24th. Zacks Investment Research lowered shares of Mylan from a buy rating to a hold rating in a research note on Wednesday, November 8th. Citigroup set a $42.00 price objective on shares of Mylan and gave the company a buy rating in a research note on Wednesday, October 4th. Finally, BidaskClub upgraded shares of Mylan from a strong sell rating to a sell rating in a research note on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company. Mylan presently has a consensus rating of Buy and an average price target of $41.49.
Shares of Mylan (MYL) traded down $0.68 on Monday, reaching $37.44. 5,736,300 shares of the company’s stock were exchanged, compared to its average volume of 5,949,535. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $20,080.00, a PE ratio of 8.11, a P/E/G ratio of 2.09 and a beta of 1.38. Mylan has a twelve month low of $29.39 and a twelve month high of $45.87.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MYL. Meeder Asset Management Inc. boosted its holdings in Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after purchasing an additional 1,475 shares during the period. BT Investment Management Ltd bought a new position in Mylan in the 3rd quarter valued at $142,000. Global X Management Co. LLC boosted its holdings in Mylan by 59.2% in the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after purchasing an additional 1,786 shares during the period. Doliver Capital Advisors LP bought a new position in Mylan in the 2nd quarter valued at $201,000. Finally, Eagle Global Advisors LLC bought a new position in Mylan in the 2nd quarter valued at $205,000. 73.86% of the stock is owned by institutional investors.
WARNING: “Mylan (MYL) Given a $46.00 Price Target at UBS” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.com-unik.info/2017/12/05/mylan-myl-given-a-46-00-price-target-at-ubs.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.